Breath Analysis of Patients Diagnosed With COVID-19 Using Infrared Spectroscopy
NCT ID: NCT04867213
Last Updated: 2021-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
200 participants
OBSERVATIONAL
2021-02-15
2022-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
SARS-CoV-2 Positive
Clinically tested for SARS-CoV-2 (as completed by standard laboratory testing e.g. RT-PCR) and with a positive result and clinical features in keeping with COVID-19 illness. The investigators aim to collect breath samples within 7 days of symptom onset in 50% of Covid positive patients, with the remaining patients breath samples collected after 7 days of symptoms onset.
No interventions assigned to this group
SARS-CoV-2 Negative
Patients with a negative RT-PCR COVID-19 test and without any clinical features to suggest COVID-19 illness.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical features in keeping with COVID-19 illness.
* Negative RT-PCR COVID-19 test
* Without any clinical features to suggest COVID-19 illness.
* No known or current features of respiratory infection, COPD, asthma, interstitial lung disease, other respiratory inflammatory conditions or lung cancer.
* Able to provide a breath sample (as based on clinical judgement).
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Breathe BioMedical Inc
INDUSTRY
McMaster University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MyLinh Duong
Professor Department of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mylinh Duong, MD
Role: PRINCIPAL_INVESTIGATOR
McMaster University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hamilton Health Sciences
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Mylinh Duong, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Cusack RP, Larracy R, Morrell CB, Ranjbar M, Le Roux J, Whetstone CE, Boudreau M, Poitras PF, Srinathan T, Cheng E, Howie K, Obminski C, O'Shea T, Kruisselbrink RJ, Ho T, Scheme E, Graham S, Beydaghyan G, Gavreau GM, Duong M. Machine learning enabled detection of COVID-19 pneumonia using exhaled breath analysis: a proof-of-concept study. J Breath Res. 2024 Mar 13;18(2). doi: 10.1088/1752-7163/ad2b6e.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12815
Identifier Type: -
Identifier Source: org_study_id